Global Regenerative Medicine 麻豆原创 Growth (Status and Outlook) 2025-2031

Publication ID:

LPI01255466

Publication Date:

February 4, 2025

Pages:

146

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Regenerative Medicine market size is predicted to grow from US$ 46260 million in 2025 to US$ 137560 million in 2031; it is expected to grow at a CAGR of 19.9% from 2025 to 2031.
Regenerative medicine is a branch of translational research in tissue engineering and molecular biology which deals with the "process of replacing, engineering or regenerating human cells, tissues or organs to restore or establish normal function". It is through the use of innovative medical means rebuilding diseased or damaged tissue or to support diseased or damaged tissue regeneration. The methods used include cell therapy, tissue engineering, chemically induced and therapeutic cloning, etc. Any combination of these technologies may be used to harness or stimulate the body鈥檚 innate healing ability in order to treat a wide range of ailments, including musculoskeletal-related conditions, cardio- and peripheral vascular diseases, neurological disorders, stroke, non-healing wounds and ocular diseases.
Regenerative medicine is defined as the process of replacing or "regenerating" human cells, tissues or organs to restore or establish normal function and has been called the "next evolution of medical treatments" and 鈥渢he vanguard of 21st century healthcare鈥� by the U.S. Department of Health and Human Services.
Global Regenerative Medicine key players include J & J (DePuy Synthes), Medtronic, Allergan(Acelity), Zimmer Biomet, etc. Global top four manufacturers hold a share about 10%.
North America is the largest market, with a share about 25%, followed by Europe, and Asia Pacific, both have a share over 40 percent.
In terms of product, Tissue Engineering is the largest segment, with a share over 40%. And in terms of application, the largest application is Dermatology, followed by Cardiovascular, CNS, Orthopedic, etc.
The 鈥淩egenerative Medicine Industry Forecast鈥� looks at past sales and reviews total world Regenerative Medicine sales in 2024, providing a comprehensive analysis by region and market sector of projected Regenerative Medicine sales for 2025 through 2031. With Regenerative Medicine sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Regenerative Medicine industry.
This Insight Report provides a comprehensive analysis of the global Regenerative Medicine landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Regenerative Medicine portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms鈥� unique position in an accelerating global Regenerative Medicine market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Regenerative Medicine and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Regenerative Medicine.
This report presents a comprehensive overview, market shares, and growth opportunities of Regenerative Medicine market by product type, application, key players and key regions and countries.
Segmentation by Type:
Cell Therapy
Tissue Engineering
Biomaterial
Other
Segmentation by Application:
Dermatology
Cardiovascular
CNS
Orthopedic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
J & J (DePuy Synthes)
Medtronic
Zimmer Biomet
Stryker
Allergan(Acelity)
MiMedx Group
Organogenesis
Fujifilm Cellular Dynamics
Osiris Therapeutics
Vcanbio
CCBC
Cytori
Celgene
Vericel Corporation
Guanhao Biotech
Mesoblast
AMAG Pharmaceuticals (CBR)
ViaCord
CordLife
Integra LifeSciences
Nuvasive
Cook Biotech
Japan Tissue Engineering

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 麻豆原创 Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 麻豆原创 Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 麻豆原创 Estimation Caveats
2 Executive Summary
2.1 World 麻豆原创 Overview
2.1.1 Global Regenerative Medicine 麻豆原创 Size (2020-2031)
2.1.2 Regenerative Medicine 麻豆原创 Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Regenerative Medicine by Country/Region (2020, 2024 & 2031)
2.2 Regenerative Medicine Segment by Type
2.2.1 Cell Therapy
2.2.2 Tissue Engineering
2.2.3 Biomaterial
2.2.4 Other
2.3 Regenerative Medicine 麻豆原创 Size by Type
2.3.1 Regenerative Medicine 麻豆原创 Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Regenerative Medicine 麻豆原创 Size 麻豆原创 Share by Type (2020-2025)
2.4 Regenerative Medicine Segment by Application
2.4.1 Dermatology
2.4.2 Cardiovascular
2.4.3 CNS
2.4.4 Orthopedic
2.4.5 Others
2.5 Regenerative Medicine 麻豆原创 Size by Application
2.5.1 Regenerative Medicine 麻豆原创 Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Regenerative Medicine 麻豆原创 Size 麻豆原创 Share by Application (2020-2025)
3 Regenerative Medicine 麻豆原创 Size by Player
3.1 Regenerative Medicine 麻豆原创 Size 麻豆原创 Share by Player
3.1.1 Global Regenerative Medicine Revenue by Player (2020-2025)
3.1.2 Global Regenerative Medicine Revenue 麻豆原创 Share by Player (2020-2025)
3.2 Global Regenerative Medicine Key Players Head office and Products Offered
3.3 麻豆原创 Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Regenerative Medicine by Region
4.1 Regenerative Medicine 麻豆原创 Size by Region (2020-2025)
4.2 Global Regenerative Medicine Annual Revenue by Country/Region (2020-2025)
4.3 Americas Regenerative Medicine 麻豆原创 Size Growth (2020-2025)
4.4 APAC Regenerative Medicine 麻豆原创 Size Growth (2020-2025)
4.5 Europe Regenerative Medicine 麻豆原创 Size Growth (2020-2025)
4.6 Middle East & Africa Regenerative Medicine 麻豆原创 Size Growth (2020-2025)
5 Americas
5.1 Americas Regenerative Medicine 麻豆原创 Size by Country (2020-2025)
5.2 Americas Regenerative Medicine 麻豆原创 Size by Type (2020-2025)
5.3 Americas Regenerative Medicine 麻豆原创 Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Regenerative Medicine 麻豆原创 Size by Region (2020-2025)
6.2 APAC Regenerative Medicine 麻豆原创 Size by Type (2020-2025)
6.3 APAC Regenerative Medicine 麻豆原创 Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Regenerative Medicine 麻豆原创 Size by Country (2020-2025)
7.2 Europe Regenerative Medicine 麻豆原创 Size by Type (2020-2025)
7.3 Europe Regenerative Medicine 麻豆原创 Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Regenerative Medicine by Region (2020-2025)
8.2 Middle East & Africa Regenerative Medicine 麻豆原创 Size by Type (2020-2025)
8.3 Middle East & Africa Regenerative Medicine 麻豆原创 Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 麻豆原创 Drivers, Challenges and Trends
9.1 麻豆原创 Drivers & Growth Opportunities
9.2 麻豆原创 Challenges & Risks
9.3 Industry Trends
10 Global Regenerative Medicine 麻豆原创 Forecast
10.1 Global Regenerative Medicine Forecast by Region (2026-2031)
10.1.1 Global Regenerative Medicine Forecast by Region (2026-2031)
10.1.2 Americas Regenerative Medicine Forecast
10.1.3 APAC Regenerative Medicine Forecast
10.1.4 Europe Regenerative Medicine Forecast
10.1.5 Middle East & Africa Regenerative Medicine Forecast
10.2 Americas Regenerative Medicine Forecast by Country (2026-2031)
10.2.1 United States 麻豆原创 Regenerative Medicine Forecast
10.2.2 Canada 麻豆原创 Regenerative Medicine Forecast
10.2.3 Mexico 麻豆原创 Regenerative Medicine Forecast
10.2.4 Brazil 麻豆原创 Regenerative Medicine Forecast
10.3 APAC Regenerative Medicine Forecast by Region (2026-2031)
10.3.1 China Regenerative Medicine 麻豆原创 Forecast
10.3.2 Japan 麻豆原创 Regenerative Medicine Forecast
10.3.3 Korea 麻豆原创 Regenerative Medicine Forecast
10.3.4 Southeast Asia 麻豆原创 Regenerative Medicine Forecast
10.3.5 India 麻豆原创 Regenerative Medicine Forecast
10.3.6 Australia 麻豆原创 Regenerative Medicine Forecast
10.4 Europe Regenerative Medicine Forecast by Country (2026-2031)
10.4.1 Germany 麻豆原创 Regenerative Medicine Forecast
10.4.2 France 麻豆原创 Regenerative Medicine Forecast
10.4.3 UK 麻豆原创 Regenerative Medicine Forecast
10.4.4 Italy 麻豆原创 Regenerative Medicine Forecast
10.4.5 Russia 麻豆原创 Regenerative Medicine Forecast
10.5 Middle East & Africa Regenerative Medicine Forecast by Region (2026-2031)
10.5.1 Egypt 麻豆原创 Regenerative Medicine Forecast
10.5.2 South Africa 麻豆原创 Regenerative Medicine Forecast
10.5.3 Israel 麻豆原创 Regenerative Medicine Forecast
10.5.4 Turkey 麻豆原创 Regenerative Medicine Forecast
10.6 Global Regenerative Medicine Forecast by Type (2026-2031)
10.7 Global Regenerative Medicine Forecast by Application (2026-2031)
10.7.1 GCC Countries 麻豆原创 Regenerative Medicine Forecast
11 Key Players Analysis
11.1 J & J (DePuy Synthes)
11.1.1 J & J (DePuy Synthes) Company Information
11.1.2 J & J (DePuy Synthes) Regenerative Medicine Product Offered
11.1.3 J & J (DePuy Synthes) Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.1.4 J & J (DePuy Synthes) Main Business Overview
11.1.5 J & J (DePuy Synthes) Latest Developments
11.2 Medtronic
11.2.1 Medtronic Company Information
11.2.2 Medtronic Regenerative Medicine Product Offered
11.2.3 Medtronic Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.2.4 Medtronic Main Business Overview
11.2.5 Medtronic Latest Developments
11.3 Zimmer Biomet
11.3.1 Zimmer Biomet Company Information
11.3.2 Zimmer Biomet Regenerative Medicine Product Offered
11.3.3 Zimmer Biomet Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.3.4 Zimmer Biomet Main Business Overview
11.3.5 Zimmer Biomet Latest Developments
11.4 Stryker
11.4.1 Stryker Company Information
11.4.2 Stryker Regenerative Medicine Product Offered
11.4.3 Stryker Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.4.4 Stryker Main Business Overview
11.4.5 Stryker Latest Developments
11.5 Allergan(Acelity)
11.5.1 Allergan(Acelity) Company Information
11.5.2 Allergan(Acelity) Regenerative Medicine Product Offered
11.5.3 Allergan(Acelity) Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.5.4 Allergan(Acelity) Main Business Overview
11.5.5 Allergan(Acelity) Latest Developments
11.6 MiMedx Group
11.6.1 MiMedx Group Company Information
11.6.2 MiMedx Group Regenerative Medicine Product Offered
11.6.3 MiMedx Group Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.6.4 MiMedx Group Main Business Overview
11.6.5 MiMedx Group Latest Developments
11.7 Organogenesis
11.7.1 Organogenesis Company Information
11.7.2 Organogenesis Regenerative Medicine Product Offered
11.7.3 Organogenesis Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.7.4 Organogenesis Main Business Overview
11.7.5 Organogenesis Latest Developments
11.8 Fujifilm Cellular Dynamics
11.8.1 Fujifilm Cellular Dynamics Company Information
11.8.2 Fujifilm Cellular Dynamics Regenerative Medicine Product Offered
11.8.3 Fujifilm Cellular Dynamics Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.8.4 Fujifilm Cellular Dynamics Main Business Overview
11.8.5 Fujifilm Cellular Dynamics Latest Developments
11.9 Osiris Therapeutics
11.9.1 Osiris Therapeutics Company Information
11.9.2 Osiris Therapeutics Regenerative Medicine Product Offered
11.9.3 Osiris Therapeutics Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.9.4 Osiris Therapeutics Main Business Overview
11.9.5 Osiris Therapeutics Latest Developments
11.10 Vcanbio
11.10.1 Vcanbio Company Information
11.10.2 Vcanbio Regenerative Medicine Product Offered
11.10.3 Vcanbio Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.10.4 Vcanbio Main Business Overview
11.10.5 Vcanbio Latest Developments
11.11 CCBC
11.11.1 CCBC Company Information
11.11.2 CCBC Regenerative Medicine Product Offered
11.11.3 CCBC Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.11.4 CCBC Main Business Overview
11.11.5 CCBC Latest Developments
11.12 Cytori
11.12.1 Cytori Company Information
11.12.2 Cytori Regenerative Medicine Product Offered
11.12.3 Cytori Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.12.4 Cytori Main Business Overview
11.12.5 Cytori Latest Developments
11.13 Celgene
11.13.1 Celgene Company Information
11.13.2 Celgene Regenerative Medicine Product Offered
11.13.3 Celgene Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.13.4 Celgene Main Business Overview
11.13.5 Celgene Latest Developments
11.14 Vericel Corporation
11.14.1 Vericel Corporation Company Information
11.14.2 Vericel Corporation Regenerative Medicine Product Offered
11.14.3 Vericel Corporation Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.14.4 Vericel Corporation Main Business Overview
11.14.5 Vericel Corporation Latest Developments
11.15 Guanhao Biotech
11.15.1 Guanhao Biotech Company Information
11.15.2 Guanhao Biotech Regenerative Medicine Product Offered
11.15.3 Guanhao Biotech Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.15.4 Guanhao Biotech Main Business Overview
11.15.5 Guanhao Biotech Latest Developments
11.16 Mesoblast
11.16.1 Mesoblast Company Information
11.16.2 Mesoblast Regenerative Medicine Product Offered
11.16.3 Mesoblast Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.16.4 Mesoblast Main Business Overview
11.16.5 Mesoblast Latest Developments
11.17 AMAG Pharmaceuticals (CBR)
11.17.1 AMAG Pharmaceuticals (CBR) Company Information
11.17.2 AMAG Pharmaceuticals (CBR) Regenerative Medicine Product Offered
11.17.3 AMAG Pharmaceuticals (CBR) Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.17.4 AMAG Pharmaceuticals (CBR) Main Business Overview
11.17.5 AMAG Pharmaceuticals (CBR) Latest Developments
11.18 ViaCord
11.18.1 ViaCord Company Information
11.18.2 ViaCord Regenerative Medicine Product Offered
11.18.3 ViaCord Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.18.4 ViaCord Main Business Overview
11.18.5 ViaCord Latest Developments
11.19 CordLife
11.19.1 CordLife Company Information
11.19.2 CordLife Regenerative Medicine Product Offered
11.19.3 CordLife Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.19.4 CordLife Main Business Overview
11.19.5 CordLife Latest Developments
11.20 Integra LifeSciences
11.20.1 Integra LifeSciences Company Information
11.20.2 Integra LifeSciences Regenerative Medicine Product Offered
11.20.3 Integra LifeSciences Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.20.4 Integra LifeSciences Main Business Overview
11.20.5 Integra LifeSciences Latest Developments
11.21 Nuvasive
11.21.1 Nuvasive Company Information
11.21.2 Nuvasive Regenerative Medicine Product Offered
11.21.3 Nuvasive Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.21.4 Nuvasive Main Business Overview
11.21.5 Nuvasive Latest Developments
11.22 Cook Biotech
11.22.1 Cook Biotech Company Information
11.22.2 Cook Biotech Regenerative Medicine Product Offered
11.22.3 Cook Biotech Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.22.4 Cook Biotech Main Business Overview
11.22.5 Cook Biotech Latest Developments
11.23 Japan Tissue Engineering
11.23.1 Japan Tissue Engineering Company Information
11.23.2 Japan Tissue Engineering Regenerative Medicine Product Offered
11.23.3 Japan Tissue Engineering Regenerative Medicine Revenue, Gross Margin and 麻豆原创 Share (2020-2025)
11.23.4 Japan Tissue Engineering Main Business Overview
11.23.5 Japan Tissue Engineering Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.